PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34779641-12 2022 We demonstrated that the model based on 18F-FDG PET/CT radiomics features combined with clinical factors could predict EGFR mutations in lung adenocarcinoma, which was expected to be an important supplement to molecular diagnosis. Fluorodeoxyglucose F18 40-47 epidermal growth factor receptor Homo sapiens 119-123 34954763-1 2022 OBJECTIVE: To develop nomograms that combine clinical characteristics, computed tomographic (CT) features and 18F-fluorodeoxyglucose PET (18F-FDG PET) metabolic parameters for individual prediction of epidermal growth factor receptor (EGFR) mutation status and exon 19 deletion mutation and exon 21 point mutation (21 L858R) subtypes in lung adenocarcinoma. Fluorodeoxyglucose F18 110-132 epidermal growth factor receptor Homo sapiens 235-239 34954763-1 2022 OBJECTIVE: To develop nomograms that combine clinical characteristics, computed tomographic (CT) features and 18F-fluorodeoxyglucose PET (18F-FDG PET) metabolic parameters for individual prediction of epidermal growth factor receptor (EGFR) mutation status and exon 19 deletion mutation and exon 21 point mutation (21 L858R) subtypes in lung adenocarcinoma. Fluorodeoxyglucose F18 138-145 epidermal growth factor receptor Homo sapiens 201-233 34957737-0 2021 Relationship between 18F-FDG PET/CT radiometabolic markers and EGFR mutation, positive ALK Expression in patients with non-small cell lung cancer. Fluorodeoxyglucose F18 21-28 epidermal growth factor receptor Homo sapiens 63-67 34957737-1 2021 Introduction: The aim of this study was to evaluate the association between the presence of EGFR mutations, ALK rearrangement and the standardized uptake value (SUV) of 18F-fluoro-2-deoxy-glucose (18F-FDG) by PET/CT imaging in patients with NSCLC. Fluorodeoxyglucose F18 197-204 epidermal growth factor receptor Homo sapiens 92-96 34908022-0 2022 Correlation of epidermal growth factor receptor mutation status and PD-L1 expression with (18F)FDG PET using volume-based parameters in non-small cell lung cancer. Fluorodeoxyglucose F18 95-98 epidermal growth factor receptor Homo sapiens 15-47 34367993-0 2021 Prediction of EGFR Mutation Status Based on 18F-FDG PET/CT Imaging Using Deep Learning-Based Model in Lung Adenocarcinoma. Fluorodeoxyglucose F18 44-51 epidermal growth factor receptor Homo sapiens 14-18 34557420-0 2021 Corrigendum: Prediction of EGFR Mutation Status Based on 18F-FDG PET/CT Imaging Using Deep Learning-Based Model in Lung Adenocarcinoma. Fluorodeoxyglucose F18 57-64 epidermal growth factor receptor Homo sapiens 27-31 34062472-0 2021 The diagnostic and predictive efficacy of 18F-FDG PET/CT metabolic parameters for EGFR mutation status in non-small-cell lung cancer: A meta-analysis. Fluorodeoxyglucose F18 42-49 epidermal growth factor receptor Homo sapiens 82-86 34062472-1 2021 PURPOSE: To investigate the predictive performance of the maximum standardized uptake value (SUVmax) and mean standardized uptake value (SUVmean) of primary lesions based on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for EGFR mutation status in patients with non-small cell lung cancer (NSCLC). Fluorodeoxyglucose F18 248-255 epidermal growth factor receptor Homo sapiens 268-272 34062472-12 2021 CONCLUSIONS: Our meta-analysis implied that SUVmax and SUVmean of primary lesions from 18F-FDG PET/CT harboured moderate predictive efficacy for the EGFR mutation status of NSCLC. Fluorodeoxyglucose F18 87-94 epidermal growth factor receptor Homo sapiens 149-153 34367993-1 2021 Objective: The purpose of this study was to develop a deep learning-based system to automatically predict epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma in 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). Fluorodeoxyglucose F18 176-198 epidermal growth factor receptor Homo sapiens 106-138 34367993-1 2021 Objective: The purpose of this study was to develop a deep learning-based system to automatically predict epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma in 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). Fluorodeoxyglucose F18 176-198 epidermal growth factor receptor Homo sapiens 140-144 34367993-1 2021 Objective: The purpose of this study was to develop a deep learning-based system to automatically predict epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma in 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). Fluorodeoxyglucose F18 200-203 epidermal growth factor receptor Homo sapiens 106-138 34367993-1 2021 Objective: The purpose of this study was to develop a deep learning-based system to automatically predict epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma in 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). Fluorodeoxyglucose F18 200-203 epidermal growth factor receptor Homo sapiens 140-144 34367993-8 2021 Conclusion: The stacking model based on 18F-FDG PET/CT images is capable to predict EGFR mutation status of patients with lung adenocarcinoma automatically and non-invasively. Fluorodeoxyglucose F18 40-47 epidermal growth factor receptor Homo sapiens 84-88 34103313-0 2021 Can 18F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? Fluorodeoxyglucose F18 4-11 epidermal growth factor receptor Homo sapiens 27-31 34103313-2 2021 OBJECTIVES: This study aimed to explore the diagnostic significance of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT for predicting the presence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC). Fluorodeoxyglucose F18 71-93 epidermal growth factor receptor Homo sapiens 173-205 34103313-2 2021 OBJECTIVES: This study aimed to explore the diagnostic significance of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT for predicting the presence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC). Fluorodeoxyglucose F18 71-93 epidermal growth factor receptor Homo sapiens 207-211 34103313-2 2021 OBJECTIVES: This study aimed to explore the diagnostic significance of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT for predicting the presence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC). Fluorodeoxyglucose F18 95-102 epidermal growth factor receptor Homo sapiens 173-205 34103313-2 2021 OBJECTIVES: This study aimed to explore the diagnostic significance of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT for predicting the presence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC). Fluorodeoxyglucose F18 95-102 epidermal growth factor receptor Homo sapiens 207-211 35515138-6 2022 In this review, we summarize the biological and clinical correlations between EGFR mutation status and 18F-FDG metabolic activity in NSCLC. Fluorodeoxyglucose F18 103-110 epidermal growth factor receptor Homo sapiens 78-82 35515138-7 2022 The metabolic activity of 18F-FDG, as an extrinsic manifestation of NSCLC, could reflect the mutation status of intrinsic factor EGFR. Fluorodeoxyglucose F18 26-33 epidermal growth factor receptor Homo sapiens 129-133 35420272-2 2022 We develop a personalized and efficient model based on 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) to predict epidermal growth factor receptor (EGFR) mutations to help identify which non-small cell cancer (NSCLC) patients are candidates for EGFR-tyrosine kinase inhibitors (TKIs) therapy. Fluorodeoxyglucose F18 79-86 epidermal growth factor receptor Homo sapiens 191-195 35420272-0 2022 Efficient 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-based machine learning model for predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Fluorodeoxyglucose F18 10-32 epidermal growth factor receptor Homo sapiens 126-158 35420272-2 2022 We develop a personalized and efficient model based on 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) to predict epidermal growth factor receptor (EGFR) mutations to help identify which non-small cell cancer (NSCLC) patients are candidates for EGFR-tyrosine kinase inhibitors (TKIs) therapy. Fluorodeoxyglucose F18 55-77 epidermal growth factor receptor Homo sapiens 191-195 35420272-2 2022 We develop a personalized and efficient model based on 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) to predict epidermal growth factor receptor (EGFR) mutations to help identify which non-small cell cancer (NSCLC) patients are candidates for EGFR-tyrosine kinase inhibitors (TKIs) therapy. Fluorodeoxyglucose F18 55-77 epidermal growth factor receptor Homo sapiens 288-292 35420272-2 2022 We develop a personalized and efficient model based on 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) to predict epidermal growth factor receptor (EGFR) mutations to help identify which non-small cell cancer (NSCLC) patients are candidates for EGFR-tyrosine kinase inhibitors (TKIs) therapy. Fluorodeoxyglucose F18 79-86 epidermal growth factor receptor Homo sapiens 157-189 35420272-2 2022 We develop a personalized and efficient model based on 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) to predict epidermal growth factor receptor (EGFR) mutations to help identify which non-small cell cancer (NSCLC) patients are candidates for EGFR-tyrosine kinase inhibitors (TKIs) therapy. Fluorodeoxyglucose F18 79-86 epidermal growth factor receptor Homo sapiens 288-292 33370365-0 2020 Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma. Fluorodeoxyglucose F18 47-54 epidermal growth factor receptor Homo sapiens 109-113 35084711-0 2022 Predictive value of multiple metabolic and heterogeneity parameters of 18F-FDG PET/CT for EGFR mutations in non-small cell lung cancer. Fluorodeoxyglucose F18 71-78 epidermal growth factor receptor Homo sapiens 90-94 35084711-1 2022 OBJECTIVES: To explore the value of multiple metabolic and heterogeneity parameters of 2-deoxy-2-(fluorine-18) fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in predicting epidermal growth factor receptor gene (EGFR) mutations in non-small cell lung cancer (NSCLC). Fluorodeoxyglucose F18 178-185 epidermal growth factor receptor Homo sapiens 208-245 35084711-1 2022 OBJECTIVES: To explore the value of multiple metabolic and heterogeneity parameters of 2-deoxy-2-(fluorine-18) fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in predicting epidermal growth factor receptor gene (EGFR) mutations in non-small cell lung cancer (NSCLC). Fluorodeoxyglucose F18 178-185 epidermal growth factor receptor Homo sapiens 247-251 35084711-10 2022 CONCLUSION: Among the metabolic and heterogeneity parameters of 18F-FDG PET/CT, low SUVmax, SUVmean, and high COV were significantly associated with EGFR mutations, and the predictive value of EGFR mutations could be enhanced when combined with clinicopathological features. Fluorodeoxyglucose F18 64-71 epidermal growth factor receptor Homo sapiens 149-153 35084711-10 2022 CONCLUSION: Among the metabolic and heterogeneity parameters of 18F-FDG PET/CT, low SUVmax, SUVmean, and high COV were significantly associated with EGFR mutations, and the predictive value of EGFR mutations could be enhanced when combined with clinicopathological features. Fluorodeoxyglucose F18 64-71 epidermal growth factor receptor Homo sapiens 193-197 35326662-0 2022 18F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs. Fluorodeoxyglucose F18 0-22 epidermal growth factor receptor Homo sapiens 153-157 35326662-1 2022 This study aims to investigate the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in early prediction of response and survival following epithelial growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy in patients with advanced lung adenocarcinomas and EGFR mutations. Fluorodeoxyglucose F18 43-65 epidermal growth factor receptor Homo sapiens 319-323 35326662-1 2022 This study aims to investigate the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in early prediction of response and survival following epithelial growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy in patients with advanced lung adenocarcinomas and EGFR mutations. Fluorodeoxyglucose F18 116-123 epidermal growth factor receptor Homo sapiens 187-220 35326662-1 2022 This study aims to investigate the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in early prediction of response and survival following epithelial growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy in patients with advanced lung adenocarcinomas and EGFR mutations. Fluorodeoxyglucose F18 116-123 epidermal growth factor receptor Homo sapiens 222-226 35326662-1 2022 This study aims to investigate the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in early prediction of response and survival following epithelial growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy in patients with advanced lung adenocarcinomas and EGFR mutations. Fluorodeoxyglucose F18 116-123 epidermal growth factor receptor Homo sapiens 319-323 32063026-1 2021 BACKGROUND: The purpose of this study was to build radiogenomics models from texture signatures derived from computed tomography (CT) and 18F-FDG PET-CT (FDG PET-CT) images of non-small cell lung cancer (NSCLC) with and without epidermal growth factor receptor (EGFR) mutations. Fluorodeoxyglucose F18 138-145 epidermal growth factor receptor Homo sapiens 228-260 32063026-1 2021 BACKGROUND: The purpose of this study was to build radiogenomics models from texture signatures derived from computed tomography (CT) and 18F-FDG PET-CT (FDG PET-CT) images of non-small cell lung cancer (NSCLC) with and without epidermal growth factor receptor (EGFR) mutations. Fluorodeoxyglucose F18 138-145 epidermal growth factor receptor Homo sapiens 262-266 33568935-0 2021 Biological Significance of 18F-FDG PET/CT Maximum Standard Uptake Value for Predicting EGFR Mutation Status in Non-Small Cell Lung Cancer Patients. Fluorodeoxyglucose F18 27-34 epidermal growth factor receptor Homo sapiens 87-91 33370365-1 2020 BACKGROUND: To investigate the survival prognostic value of the radiomic features of 18F-FDG PET in patients who had EGFR (epidermal growth factor receptor) mutated lung adenocarcinoma and received targeted TKI (tyrosine kinase inhibitor) treatment. Fluorodeoxyglucose F18 85-92 epidermal growth factor receptor Homo sapiens 117-121 33370365-1 2020 BACKGROUND: To investigate the survival prognostic value of the radiomic features of 18F-FDG PET in patients who had EGFR (epidermal growth factor receptor) mutated lung adenocarcinoma and received targeted TKI (tyrosine kinase inhibitor) treatment. Fluorodeoxyglucose F18 85-92 epidermal growth factor receptor Homo sapiens 123-155 33262942-0 2020 Value of 18F-FDG PET/CT-Based Radiomics Nomogram to Predict Survival Outcomes and Guide Personalized Targeted Therapy in Lung Adenocarcinoma With EGFR Mutations. Fluorodeoxyglucose F18 9-16 epidermal growth factor receptor Homo sapiens 146-150 33011375-0 2020 Value of interim 18F-FDG PET/CT for predicting progression-free survival in stage IIIB/IV EGFR-mutant non-small-cell lung cancer patients with EGFR-TKI therapy. Fluorodeoxyglucose F18 17-24 epidermal growth factor receptor Homo sapiens 90-94 32815896-0 2020 Primary metabolic tumor volume from 18F-FDG PET/CT associated with epidermal growth factor receptor mutation in lung adenocarcinoma patients. Fluorodeoxyglucose F18 36-43 epidermal growth factor receptor Homo sapiens 67-99 33011375-1 2020 OBJECTIVES: We retrospectively investigated the prognostic value of FDG-PET performed for patients with Stage IIIB/IV EGFR-mutant non-small-cell lung cancer (NSCLC) receiving EGFR tyrosine kinase inhibitor (TKI) therapy. Fluorodeoxyglucose F18 68-71 epidermal growth factor receptor Homo sapiens 118-122 33011375-1 2020 OBJECTIVES: We retrospectively investigated the prognostic value of FDG-PET performed for patients with Stage IIIB/IV EGFR-mutant non-small-cell lung cancer (NSCLC) receiving EGFR tyrosine kinase inhibitor (TKI) therapy. Fluorodeoxyglucose F18 68-71 epidermal growth factor receptor Homo sapiens 175-179 33134170-0 2020 Performance of 18F-FDG PET/CT Radiomics for Predicting EGFR Mutation Status in Patients With Non-Small Cell Lung Cancer. Fluorodeoxyglucose F18 15-22 epidermal growth factor receptor Homo sapiens 55-59 33067442-4 2020 Herein, we report a 18F-FDG-PET/CT-based deep learning model, which demonstrates high accuracy in EGFR mutation status prediction across patient cohorts from different institutions. Fluorodeoxyglucose F18 20-27 epidermal growth factor receptor Homo sapiens 98-102 33134170-1 2020 Objective: To assess the performance of pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) radiomics features for predicting EGFR mutation status in patients with non-small cell lung cancer (NSCLC). Fluorodeoxyglucose F18 53-75 epidermal growth factor receptor Homo sapiens 176-180 33134170-1 2020 Objective: To assess the performance of pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) radiomics features for predicting EGFR mutation status in patients with non-small cell lung cancer (NSCLC). Fluorodeoxyglucose F18 126-133 epidermal growth factor receptor Homo sapiens 176-180 33134170-10 2020 Conclusions: EGFR mutations status in patients with NSCLC could be well predicted by the combined model based on 18F-FDG PET/CT radiomics and clinical feature, providing an alternative useful method for the selection of targeted therapy. Fluorodeoxyglucose F18 113-120 epidermal growth factor receptor Homo sapiens 13-17 32863894-0 2020 18F-FDG PET/CT SUVmax and serum CEA levels as predictors for EGFR mutation state in Chinese patients with non-small cell lung cancer. Fluorodeoxyglucose F18 0-7 epidermal growth factor receptor Homo sapiens 61-65 32863894-9 2020 The ROC analysis indicated that an 18F-FDG PET/CT uptake SUVmax >11.5 may be a predictor of the wild-type EGFR genotype and increased CEA levels (CEA >9.4 ng/ml) were associated with EGFR mutations. Fluorodeoxyglucose F18 35-42 epidermal growth factor receptor Homo sapiens 106-110 32801885-0 2020 Diagnostic and Predictive Values of 18F-FDG PET/CT Metabolic Parameters in EGFR-Mutated Advanced Lung Adenocarcinoma. Fluorodeoxyglucose F18 36-43 epidermal growth factor receptor Homo sapiens 75-79 32863894-9 2020 The ROC analysis indicated that an 18F-FDG PET/CT uptake SUVmax >11.5 may be a predictor of the wild-type EGFR genotype and increased CEA levels (CEA >9.4 ng/ml) were associated with EGFR mutations. Fluorodeoxyglucose F18 35-42 epidermal growth factor receptor Homo sapiens 183-187 32831963-12 2020 Conclusion: In Asian NSCLC/ADC patients, SUVmax, MTV, and ASP on FDG PET are significantly related to EGFR mutation status. Fluorodeoxyglucose F18 65-68 epidermal growth factor receptor Homo sapiens 102-106 32801885-1 2020 Purpose: The clinical implications of the metabolic parameters of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) in epidermal growth factor receptor (EGFR)-mutated lung cancer are not fully understood. Fluorodeoxyglucose F18 66-88 epidermal growth factor receptor Homo sapiens 158-190 32801885-1 2020 Purpose: The clinical implications of the metabolic parameters of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) in epidermal growth factor receptor (EGFR)-mutated lung cancer are not fully understood. Fluorodeoxyglucose F18 66-88 epidermal growth factor receptor Homo sapiens 192-196 32801885-1 2020 Purpose: The clinical implications of the metabolic parameters of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) in epidermal growth factor receptor (EGFR)-mutated lung cancer are not fully understood. Fluorodeoxyglucose F18 139-146 epidermal growth factor receptor Homo sapiens 158-190 32801885-1 2020 Purpose: The clinical implications of the metabolic parameters of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) in epidermal growth factor receptor (EGFR)-mutated lung cancer are not fully understood. Fluorodeoxyglucose F18 139-146 epidermal growth factor receptor Homo sapiens 192-196 32801885-9 2020 Conclusion: SUVmax may be predictive for EGFR mutational status, and MTV and TLG of primary tumors may be promising prognostic parameters; 18F-FDG PET/CT has potential utility for the risk stratification of EGFR-mutated patients treated with targeted therapy. Fluorodeoxyglucose F18 139-146 epidermal growth factor receptor Homo sapiens 207-211 31532771-2 2019 Our group recently showed in breast cancer patients that EGFR expression is strongly correlated with high tumor uptake of the glucose analogue, 18F-fluorodeoxyglucose (FDG). Fluorodeoxyglucose F18 144-166 epidermal growth factor receptor Homo sapiens 57-61 32742498-2 2020 We investigated the predictive role of 18F-FDG PET/CT and clinicopathological features for EGFR mutations in lung adenocarcinoma with bone metastasis. Fluorodeoxyglucose F18 39-46 epidermal growth factor receptor Homo sapiens 91-95 32676319-0 2020 Predicting EGFR mutation subtypes in lung adenocarcinoma using 18F-FDG PET/CT radiomic features. Fluorodeoxyglucose F18 63-70 epidermal growth factor receptor Homo sapiens 11-15 32676319-3 2020 In this study, we aimed to develop a predictive model based on 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) radiomic features to identify the specific EGFR mutation subtypes. Fluorodeoxyglucose F18 63-85 epidermal growth factor receptor Homo sapiens 195-199 32676319-3 2020 In this study, we aimed to develop a predictive model based on 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) radiomic features to identify the specific EGFR mutation subtypes. Fluorodeoxyglucose F18 136-143 epidermal growth factor receptor Homo sapiens 195-199 32676320-0 2020 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiomic features for prediction of epidermal growth factor receptor mutation status and prognosis in patients with lung adenocarcinoma. Fluorodeoxyglucose F18 0-22 epidermal growth factor receptor Homo sapiens 114-146 31659591-0 2020 Usefulness of gradient tree boosting for predicting histological subtype and EGFR mutation status of non-small cell lung cancer on 18F FDG-PET/CT. Fluorodeoxyglucose F18 131-138 epidermal growth factor receptor Homo sapiens 77-81 31681597-0 2019 Predictive Power of a Radiomic Signature Based on 18F-FDG PET/CT Images for EGFR Mutational Status in NSCLC. Fluorodeoxyglucose F18 50-57 epidermal growth factor receptor Homo sapiens 76-80 31532771-2 2019 Our group recently showed in breast cancer patients that EGFR expression is strongly correlated with high tumor uptake of the glucose analogue, 18F-fluorodeoxyglucose (FDG). Fluorodeoxyglucose F18 168-171 epidermal growth factor receptor Homo sapiens 57-61 31532771-9 2019 Blocking EGFR activation with BIBX1382 or gefitinib completely abolished both FDG uptake and proliferation effects. Fluorodeoxyglucose F18 78-81 epidermal growth factor receptor Homo sapiens 9-13 30776196-1 2019 BACKGROUND: The purpose of this study was to investigate an association between EGFR mutation status and 18 F-fluorodeoxyglucose positron emission tomography-computed tomography (18 F-FDG PET-CT) image features in lung adenocarcinoma. Fluorodeoxyglucose F18 179-187 epidermal growth factor receptor Homo sapiens 80-84 31126985-3 2019 Clinical responses to the EGFR-targeting TKIs are evaluated through 2-[18F]fluoro-2-deoxy-glucose (18FDG)-PET uptake, which is decreased in patients responding favorably to therapy and is positively correlated with survival. Fluorodeoxyglucose F18 99-104 epidermal growth factor receptor Homo sapiens 26-30 30776196-10 2019 CONCLUSION: Quantitative parameters based on 18 F-FDG PET-CT have modest power to predict the presence of EGFR mutation in lung adenocarcinoma; however, when compared to smoking history, they are not good or significant predictive factors. Fluorodeoxyglucose F18 45-53 epidermal growth factor receptor Homo sapiens 106-110 30320488-1 2019 The aim of this study is to investigate the role of CD147 in glucose metabolic regulation and its association with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment sensitivity prediction using 18 F-fluorodeoxyglucose (18 F-FDG) PET/CT imaging in non-small cell lung cancer (NSCLC). Fluorodeoxyglucose F18 230-249 epidermal growth factor receptor Homo sapiens 149-153 26359571-1 2015 PURPOSE: Data in the literature regarding the use of F-FDG avidity of non-small cell lung cancer (NSCLC) as an imaging biomarker to predict the status of epidermal growth factor receptor (EGFR) mutation are conflicting. Fluorodeoxyglucose F18 55-58 epidermal growth factor receptor Homo sapiens 154-186 29547059-4 2018 RESULTS: The values of all the metabolic and volumetric FDG PET/CT parameters were significantly lower in EGFR mutant than in EGFR wild-type lung adenocarcinomas. Fluorodeoxyglucose F18 56-59 epidermal growth factor receptor Homo sapiens 106-110 29547059-4 2018 RESULTS: The values of all the metabolic and volumetric FDG PET/CT parameters were significantly lower in EGFR mutant than in EGFR wild-type lung adenocarcinomas. Fluorodeoxyglucose F18 56-59 epidermal growth factor receptor Homo sapiens 126-130 30431083-0 2019 EGFR mutation decreases FDG uptake in non-small cell lung cancer via the NOX4/ROS/GLUT1 axis. Fluorodeoxyglucose F18 24-27 epidermal growth factor receptor Homo sapiens 0-4 30431083-2 2019 The association between the maximum standardized uptake value (SUVmax) from 18F-FDG PET-CT scanning and epidermal growth factor receptor (EGFR) mutation status has, to the best of our knowledge, not previously been fully elucidated, and the potential mechanisms by which EGFR mutations alter FDG uptake are largely unknown. Fluorodeoxyglucose F18 80-83 epidermal growth factor receptor Homo sapiens 104-136 30431083-2 2019 The association between the maximum standardized uptake value (SUVmax) from 18F-FDG PET-CT scanning and epidermal growth factor receptor (EGFR) mutation status has, to the best of our knowledge, not previously been fully elucidated, and the potential mechanisms by which EGFR mutations alter FDG uptake are largely unknown. Fluorodeoxyglucose F18 80-83 epidermal growth factor receptor Homo sapiens 138-142 30431083-2 2019 The association between the maximum standardized uptake value (SUVmax) from 18F-FDG PET-CT scanning and epidermal growth factor receptor (EGFR) mutation status has, to the best of our knowledge, not previously been fully elucidated, and the potential mechanisms by which EGFR mutations alter FDG uptake are largely unknown. Fluorodeoxyglucose F18 80-83 epidermal growth factor receptor Homo sapiens 271-275 28881771-0 2017 Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET/CT metrics. Fluorodeoxyglucose F18 90-93 epidermal growth factor receptor Homo sapiens 14-18 28881771-6 2017 The maximum standardized uptake value (SUVmax) of FDG uptake in lung lesions was a predictive factor of the EGFR mutations (p = 0.029), while metabolic tumor volume and total lesion glycolysis were not predictive. Fluorodeoxyglucose F18 50-53 epidermal growth factor receptor Homo sapiens 108-112 27597275-2 2016 The purpose of this study was to determine the association of (18)F-2-fluoro-2-deoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) metrics with T790M status after acquiring resitance to EGFR-TKI resistance. Fluorodeoxyglucose F18 68-91 epidermal growth factor receptor Homo sapiens 209-213 26998075-0 2016 Association between histopathological subtype, 18F-fluorodeoxyglucose uptake and epidermal growth factor receptor mutations in lung adenocarcinoma. Fluorodeoxyglucose F18 47-69 epidermal growth factor receptor Homo sapiens 81-113 26998075-1 2016 The aim of the present study was to investigate the association between histopathological subtypes, epidermal growth factor receptor (EGFR) mutations and 18F-fluorodeoxyglucose (FDG) uptake in patients with lung adenocarcinoma (ADC). Fluorodeoxyglucose F18 154-176 epidermal growth factor receptor Homo sapiens 100-132 26998075-1 2016 The aim of the present study was to investigate the association between histopathological subtypes, epidermal growth factor receptor (EGFR) mutations and 18F-fluorodeoxyglucose (FDG) uptake in patients with lung adenocarcinoma (ADC). Fluorodeoxyglucose F18 154-176 epidermal growth factor receptor Homo sapiens 134-138 26998075-1 2016 The aim of the present study was to investigate the association between histopathological subtypes, epidermal growth factor receptor (EGFR) mutations and 18F-fluorodeoxyglucose (FDG) uptake in patients with lung adenocarcinoma (ADC). Fluorodeoxyglucose F18 178-181 epidermal growth factor receptor Homo sapiens 100-132 26998075-1 2016 The aim of the present study was to investigate the association between histopathological subtypes, epidermal growth factor receptor (EGFR) mutations and 18F-fluorodeoxyglucose (FDG) uptake in patients with lung adenocarcinoma (ADC). Fluorodeoxyglucose F18 178-181 epidermal growth factor receptor Homo sapiens 134-138 26632406-0 2016 Relationship between Preoperative 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Status in Primary Colorectal Cancer. Fluorodeoxyglucose F18 34-56 epidermal growth factor receptor Homo sapiens 68-100 26632406-2 2016 The aim of this study was to investigate a possible association between 18F-FDG uptake on preoperative positron emission tomography/computed tomography (PET/CT) and EGFR status in primary CRC. Fluorodeoxyglucose F18 72-79 epidermal growth factor receptor Homo sapiens 165-169 26632406-11 2016 Preoperative SUVmax of 18F-FDG may have a limited role in predicting EGFR expression in such tumors because of its poor specificity. Fluorodeoxyglucose F18 23-30 epidermal growth factor receptor Homo sapiens 69-73 26359571-1 2015 PURPOSE: Data in the literature regarding the use of F-FDG avidity of non-small cell lung cancer (NSCLC) as an imaging biomarker to predict the status of epidermal growth factor receptor (EGFR) mutation are conflicting. Fluorodeoxyglucose F18 55-58 epidermal growth factor receptor Homo sapiens 188-192 17020967-2 2006 EXPERIMENTAL DESIGN: We investigated whether tumors responding to EGFR inhibitors can be identified by measuring treatment-induced changes in glucose utilization by positron emission tomography with the glucose analogue fluorodeoxyglucose (FDG-PET). Fluorodeoxyglucose F18 220-238 epidermal growth factor receptor Homo sapiens 66-70 24852187-3 2014 The aim of this study was to predict EGFR mutation status in patients with pulmonary adenocarcinoma based on (18)F-fluorodeoxyglucose (FDG) uptake and imaging features in positron emission tomography/computed tomography (PET/CT), as well as on the serum carcinoembryonic antigen (CEA) level. Fluorodeoxyglucose F18 135-138 epidermal growth factor receptor Homo sapiens 37-41 23489365-2 2013 We analysed positron emission tomography with fluorodeoxyglucose SUVmax in 14 patients with EGFR mutations, and a control group of 14 subjects with wild-type EGFR adenocarcinomas. Fluorodeoxyglucose F18 46-64 epidermal growth factor receptor Homo sapiens 92-96 21339258-0 2011 Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Fluorodeoxyglucose F18 8-30 epidermal growth factor receptor Homo sapiens 74-106 21339258-11 2011 CONCLUSIONS: In this retrospective study, high FDG avidity (normalized SUV(max) >= 5) correlated with EGFR-wild-type genotype. Fluorodeoxyglucose F18 47-50 epidermal growth factor receptor Homo sapiens 105-109 17020967-2 2006 EXPERIMENTAL DESIGN: We investigated whether tumors responding to EGFR inhibitors can be identified by measuring treatment-induced changes in glucose utilization by positron emission tomography with the glucose analogue fluorodeoxyglucose (FDG-PET). Fluorodeoxyglucose F18 240-243 epidermal growth factor receptor Homo sapiens 66-70